These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

880 related items for PubMed ID: 19737568

  • 1. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL.
    Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
    [Abstract] [Full Text] [Related]

  • 2. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.
    Chen CH, Lee CM, Hung CH, Wang JH, Hu TH, Changchien CS, Lu SN.
    J Gastroenterol Hepatol; 2011 Mar; 26(3):461-8. PubMed ID: 21332543
    [Abstract] [Full Text] [Related]

  • 3. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.
    Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Brunetto MR, Farci P, Popescu M, McCloud P, Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group.
    Gut; 2007 May; 56(5):699-705. PubMed ID: 17127704
    [Abstract] [Full Text] [Related]

  • 4. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.
    Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL.
    Gastroenterology; 2012 Mar; 142(3):513-520.e1. PubMed ID: 22108195
    [Abstract] [Full Text] [Related]

  • 5. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL.
    Antivir Ther; 2012 Mar; 17(1):9-17. PubMed ID: 22267464
    [Abstract] [Full Text] [Related]

  • 6. Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B.
    Zhu H, Wang C, Zhang Y, Wei S, Li X, Zhang Z.
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1963-1970. PubMed ID: 27075693
    [Abstract] [Full Text] [Related]

  • 7. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.
    PLoS One; 2015 Dec; 10(4):e0122259. PubMed ID: 25835020
    [Abstract] [Full Text] [Related]

  • 8. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.
    Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL.
    Hepatology; 2013 Sep; 58(3):872-80. PubMed ID: 23553752
    [Abstract] [Full Text] [Related]

  • 9. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [Abstract] [Full Text] [Related]

  • 10. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
    Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, Rothe V, Regep L, Bonino F.
    J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
    [Abstract] [Full Text] [Related]

  • 11. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
    Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, Liu CH, Kuo SF, Pan CJ, Yang SS, Su CW, Chen PJ, Chen DS, Kao JH.
    Antivir Ther; 2011 Dec; 16(5):629-37. PubMed ID: 21817184
    [Abstract] [Full Text] [Related]

  • 12. HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo.
    Hansen BE, Rijckborst V, Ter Borg MJ, Janssen HL.
    J Med Virol; 2011 Nov; 83(11):1917-23. PubMed ID: 21915866
    [Abstract] [Full Text] [Related]

  • 13. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
    Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL.
    Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787
    [Abstract] [Full Text] [Related]

  • 14. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.
    Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL.
    Gastroenterology; 2008 Aug; 135(2):459-67. PubMed ID: 18585385
    [Abstract] [Full Text] [Related]

  • 15. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q, Chen F, Shao X, Zhang X, Zhao Z, Gao Z.
    Antivir Ther; 2015 Aug; 20(2):217-24. PubMed ID: 25138110
    [Abstract] [Full Text] [Related]

  • 16. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
    Gish RG, Lau DT, Schmid P, Perrillo R.
    Am J Gastroenterol; 2007 Dec; 102(12):2718-23. PubMed ID: 17662102
    [Abstract] [Full Text] [Related]

  • 17. Intensification of treatment with pegylated interferon alfa in patients coinfected with HIV and HBV genotype H or G being treated with a tenofovir/emtricitabine-containing regimen.
    Mata-Marín JA, Mata-Marín LA, Arroyo-Anduiza CI, Huerta-García G, Sandoval-Ramirez JL, Manjarrez-Tellez B, Gaytán-Martínez JE.
    Hepatogastroenterology; 2014 Dec; 61(133):1187-91. PubMed ID: 25436280
    [Abstract] [Full Text] [Related]

  • 18. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
    Lampertico P, Viganò M, Colombo M.
    Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
    [Abstract] [Full Text] [Related]

  • 19. Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients.
    Wang CT, Zhang YF, Sun BH, Dai Y, Zhu HL, Xu YH, Lu MJ, Yang DL, Li X, Zhang ZH.
    World J Gastroenterol; 2015 May 14; 21(18):5668-76. PubMed ID: 25987794
    [Abstract] [Full Text] [Related]

  • 20. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
    Ma H, Yang RF, Wei L.
    J Gastroenterol Hepatol; 2010 Sep 14; 25(9):1498-506. PubMed ID: 20796146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.